Anebulo Pharmaceuticals (ANEB)

Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.

Company profile

Ticker

ANEB

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

SEC CIK

0001815974

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

851170950

ANEB stock data

1M 1Y 5Y

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022

27 Jul 22

Ladenburg Thalmann Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $6

27 Jul 22

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and announces Price Target of $6.

Why Cannabis Companies Traded Higher; Here's 60 Biggest Movers From Yesterday

15 Jul 22

Gainers

12 Health Care Stocks Moving In Thursday's Intraday Session

14 Jul 22

Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session

14 Jul 22

Press releases

From Benzinga Pro

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

5 Jul 22

Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals,

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

23 Jun 22

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

24 May 22

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 May 22

11 Aug 22

30 Jun 23

Financial summary

Financial statements Chart ANEB financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

ANEB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 22	Cundy Kenneth C	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	2.91	350,169	1.02M	350,169
7 Feb 22	Simon Allen	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	6.15	625,000	3.84M	625,000
17 Dec 21	Aron R. English	Common Stock, par value $0.001 per share	Buy	Acquire P	Yes	No	6.5858	400	2.63K	3,362,713

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ANEB institutional ownership history Ownership history

37.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	3	+233.3%
Opened positions	8	1	+700.0%
Closed positions	1	8	-87.5%
Increased positions	0	1	EXIT
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	29.54M	52K	+56705.8%
Total shares	8.84M	4.66M	+89.7%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Aron R. English	4.65M	$0	0.0%
22NW	3.36M	$23.81M	NEW
Mangrove Partners	399.22K	$2.83M	NEW
Laurion Capital Management	219.58K	$1.48M	NEW
Ikarian Capital	181.2K	$1.23M	NEW
Boothbay Fund Management	17.33K	$123K	NEW
BLK Blackrock	7.45K	$53K	-4.6%
UBS UBS Group AG - Registered Shares	2.16K	$15K	NEW
Tower Research Capital	756	$5K	NEW
MS Morgan Stanley	3	$0	NEW

Largest transactions	Shares	Bought/sold	Change
22NW	3.36M	+3.36M	NEW
Mangrove Partners	399.22K	+399.22K	NEW
Laurion Capital Management	219.58K	+219.58K	NEW
Ikarian Capital	181.2K	+181.2K	NEW
Boothbay Fund Management	17.33K	+17.33K	NEW
UBS UBS Group AG - Registered Shares	2.16K	+2.16K	NEW
Tower Research Capital	756	+756	NEW
Advisor	0	-500	EXIT
BLK Blackrock	7.45K	-360	-4.6%
MS Morgan Stanley	3	+3	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Opiant Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Jumpstart, repayment, smaller

Removed: applicability, assessed, ASU, beginning, closed, conformity, currency, declared, demand, director, existing, exposed, exposure, FASB, indirectly, minimal, previously, quarter, registration, removing, repaid, Simplifying, subsequent, tax, Topic

From filing 10-Q 2022 Q3

Financial reports